HIST3H2A is a potential biomarker for pancreatic cancer: A study based on TCGA data

The family of histone H2A proved that there are a lot of variants associated with cancer development. The link between HIST3H2A and pancreatic cancer has never been noted before. Our research suggests that HIST3H2A affects pancreatic tumor immune process and prognosis of patients, through the JAK STAT pathway, so it is expected to become the biomarker of pancreatic cancer.Gene expression profiles and clinical data of pancreatic cancer patients were downloaded from The Cancer Genome Atlas database (TCGA) and The Genotype Tissue Expression (GETx) project. R software (Rx64 3.6.0) was utilized to analyze. Gene set enrichment analysis (GSEA) was used to analyze HIST3H2A related signaling pathways in pancreatic cancer. CIBERSORT is applied to estimate the compositional patterns of the 22 types of immune cell fraction based on bulk expression data.HIST3H2A was expressed at higher in pancreatic cancer tissues than normal pancreatic tissues. Kaplan-Meier survival analysis suggested that the level of HIST3H2A expression affect prognosis of pancreatic cancer patients. Univariate Cox analysis and Multivariate Cox analysis suggested that HIST3H2A expression is a prognostic factor of pancreatic cancer. Cor expression analysis indicated that the genes positively correlated with HIST3H2A expression trend were DCST1-AS1, HIST1H2BD, SLC12A9-AS1. GSEA showed that the JAK-STAT signaling pathway was enriched in the HIST3H2A high expression phenotype, whereas intestinal network for IgA production, Asthma and Chemokine signaling pathway were enriched in the HIST3H2A low expression phenotype. In additional, results showed that CD8 T cells (P = .007), activated CD4 memory T cells (P = .001), and monocytes (P = .002) were more abundant in lower HIST3H2A expression groups.HIST3H2A is a promising biomarker for predicting prognosis of pancreatic cancer, and it could be a potential therapeutic target. HIST3H2A might regulate the progression of tumor immune in pancreatic cancer through modulating the JAK-STAT pathway. In addition, the role HIST3H2A in pancreatic cancer may be related to DCST1-AS1, HIST1H2B, SLC12A9-AS1. However, more research is necessary to validate findings.